Andy Ransom, CEO, said: “We have made a positive overall start to 2024. The Group has performed well and our RIGHT WAY 2 plan has delivered a stabilising performance in North America. With the key trading period for the business ahead of us, we remain confident in delivering on our guidance of 2-4% Organic Revenue growth in the region. As the year proceeds, we look forward to continued progress, driven by our focus on North America growth and the Terminix integration plan, which is in the advanced stages of preparation for the first full branch integrations commencing mid-year.” ADRs of Rentokil are down 7% in pre-market at $26.32.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
